Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026

Foghorn Therapeutics Inc.

2024-Q1 EPS reported -$0.59 revenue$5,050,000

Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.
Cash $206.7M as of Mar 31, 2024; expected cash runway into first half of 2026.
FHD-286 combo in AML dose escalation ongoing; initial clinical data expected H2 2024.
IND submitted for FHD-909 (first-in-class oral BRM selective inhibitor); Phase 1 in BRG1-mutated NSCLC expected H2 2024.
Appointed Kristian Humer as CFO in April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-020454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.